Date: 2017-01-09
Type of information: Services contract
Compound: Epogen® (epoetin alfa) and Aranesp® (darbepoetin alfa)
Company: Amgen (USA - CA) DaVita (USA - CO)
Therapeutic area: Kidney diseases - Metabolic diseases - Renal diseases
Type agreement: supply services
Action mechanism: protein
Disease:
Details: * On January 9, 2017, Amgen announced it has entered into a six-year Sourcing and Supply Agreement with DaVita Inc. This is a continuation of Amgen's long-term relationship with DaVita that is focused on serving dialysis patients. Under the terms of the new agreement, Amgen will supply DaVita with Epogen® (epoetin alfa) and Aranesp® (darbepoetin alfa) in amounts necessary to meet a specified annual percentage of DaVita's and its affiliates' requirements for erythropoiesis-stimulating agents used in providing dialysis services in the United States and Puerto Rico . The percentage varies during the term of the new agreement from Jan. 6, 2017 , through Dec. 31, 2022 , but in each year is at least 90 percent. The new agreement will replace the Sourcing and Supply Agreement dated Nov. 15, 2011 , between Amgen and DaVita that would have expired on Dec. 31, 2018.
Financial terms:
Latest news:
